Vaxcyte PCVX
NASDAQ PCVX
$66.85 +0.62 (+0.94%)
As of: Oct 21, 2026 · 9:53 AM EDT

Vaxcyte (PCVX) Other Operating Expenses (2022 - 2023)

Updated

Vaxcyte's Other Operating Expenses came in at $75 million for Q4 2023, up 226.2% from $23 million a year earlier.

Analysis

Vaxcyte (PCVX) Other Operating Expenses (2022 - 2023) Analysis & Trends

  • Going back by year, Other Operating Expenses was $23 million in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,139.37 Bn 1,107.95 Bn 19.71 Bn
2 Johnson & Johnson 618.39 Bn 536.92 Bn 17.26 Bn
3 AbbVie 508.07 Bn 481.19 Bn 12.70 Bn
4 Merck 367.07 Bn 321.44 Bn 12.21 Bn
5 Novartis Ag 298.65 Bn 262.64 Bn 11.24 Bn
6 Astrazeneca 263.08 Bn 236.77 Bn 12.86 Bn
7 Amgen 236.65 Bn 192.05 Bn 7.24 Bn
8 Gilead Sciences 192.73 Bn 166.92 Bn 6.22 Bn
9 Pfizer 171.28 Bn 117.93 Bn 10.94 Bn
10 Vaxcyte 9.69 Bn 3.19 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 75.00 Mn
Dec 31, 2022 23.00 Mn
API Access

Vaxcyte Other Operating Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-operating-expenses&ticker=PCVX&period=max&api_key=YOUR_API_KEY